Scope and Claims of US Patent 8,741,904 (Rifaximin Polymorphs δ and ε): What the Patent Covers and Where Generics/Competitors Can Design Around
US Drug Patent 8,741,904 is directed to rifaximin polymorphic forms δ and ε, defined by specific X-ray powder diffraction (XRPD) peak positions (2-θ, ±0.2°) and, for δ, specific water-content ranges. The claims also extend to therapeutic use in gastrointestinal bacterial activity, plus medicinal preparations for oral and topical administration containing the specified polymorphs.
The practical scope is narrow in one key way: the patent’s compound identity is locked to XRPD peak fingerprints. That makes polymorph control, XRPD method adherence, and moisture management the main infringement levers. At the same time, the claims are broad in application: they cover treatment methods and formulations (oral and topical) so long as the active ingredient polymorph matches the claimed XRPD/water parameters.
What does US 8,741,904 claim for rifaximin polymorph δ (XRPD + water content)?
Core product claim scope (compound identity). The patent claims rifaximin in polymorphic form δ where XRPD shows at least the following peaks (Claim 1):
- ~5.7° ±0.2 2-θ
- ~12.1° ±0.2 2-θ
- ~17.0° ±0.2 2-θ
Additional-dependent claim narrowing (Claim 2-5 and others). The dependent claim set materially tightens the XRPD fingerprint by requiring additional peaks, culminating in a broader “full fingerprint” style claim (Claim 5) that includes a long list of peaks:
- ~5.7
- ~6.7
- ~7.1
- ~8.0
- ~8.7
- ~10.4
- ~11.3
- ~12.1
- ~17.0
- ~17.3
- ~17.5
- ~18.5
- ~18.8
- ~19.1
- ~21.0
- ~21.5
(all 2-θ with ±0.2°)
Water-content constraints (Claim 6-7). The δ polymorph is also characterized by moisture:
- Claim 6: water content between 3% and 4.5%
- Claim 7: water content between 2.5% and 6%
Implication for infringement. A competitor attempting to avoid claim 1 can aim for:
- XRPD fingerprint mismatch (shifting peaks outside ±0.2° tolerances under the same measurement conditions), and/or
- different polymorph identity (not “form δ”), and/or
- water content outside the claimed range (where those claims are asserted, notably claims 6-7).
Because the independent “compound” claim 1 does not explicitly recite water content, moisture-based design-around primarily attacks the water-limited dependent claims, not claim 1.
What does US 8,741,904 claim for rifaximin polymorph ε (XRPD only)?
Core product claim scope (compound identity). The patent claims rifaximin in polymorphic form ε (Claim 8) defined by XRPD peaks:
- ~8.2° ±0.2 2-θ
- ~12.4° ±0.2 2-θ
- ~16.3° ±0.2 2-θ
Dependent claim tightening (Claim 22-23). Additional peaks are required in dependent claims:
- Claim 22 adds: ~8.7, ~10.3, ~11.1, ~11.7
- Claim 23 adds: ~7.0, ~10.3, ~14.5, ~17.2
No explicit water constraints in ε claims provided. In the text supplied, ε is defined by XRPD peaks only, without a recited water-content range in the ε claim set.
Implication. Design-around for ε targets XRPD fingerprint control. Moisture changes may still affect polymorph stability, but based on the claims provided, the infringement defense is primarily XRPD-based rather than water-content-based.
What treatment method claims are included in US 8,741,904 (GI bacterial activity)?
The patent includes method-of-treatment claims using the polymorphs as actives. The method language is functional: reduce bacterial activity in the GI tract.
For δ:
- Claim 9: administering a pharmaceutical composition containing therapeutically effective rifaximin δ with XRPD peaks ~5.7, ~12.1, ~17.0
- Claim 10: bacterial activity causes infectious diarrhea
- Claim 11: bacteria are anaerobic bacteria
- Claim 12: composition administered orally
- Claim 13: bacteria are gastrointestinal bacteria
For ε:
- Claim 14: administering a pharmaceutical composition containing therapeutically effective rifaximin ε with XRPD peaks ~8.2, ~12.4, ~16.3
- Claim 15: infectious diarrhea
- Claim 16: anaerobic bacteria
- Claim 17: oral administration
- Claim 18: gastrointestinal bacteria
Risk note for generics. If a generic manufacturing process yields a product whose polymorph is within the claimed XRPD window, method claims increase litigation exposure even if the active is already “approved” for GI indications. The claims are not limited to a specific branded indication label; they cover GI bacterial activity and its clinical manifestations.
What formulation claims are included: oral vs topical medicinal preparations?
The patent extends from active polymorph identity to medicinal preparations.
Oral medicinal preparations
-
Claim 24: oral medicinal preparation with antibiotic activity comprising rifaximin δ with XRPD peaks ~5.7, ~12.1, ~17.0
-
Claims 25-32: additional δ XRPD peak requirements and water-content limits (3%–4.5% and 2.5%–6%)
-
Claim 33: oral medicinal preparation with antibiotic activity comprising rifaximin ε with XRPD peaks ~8.2, ~12.4, ~16.3
-
Claims 34-35: expanded ε XRPD fingerprint requirements
Topical medicinal preparations
- Claim 36: topical medicinal preparation with antibiotic activity comprising rifaximin δ with XRPD peaks ~5.7, ~12.1, ~17.0
- Claims 37-44: dependent narrowing for δ, including additional XRPD peaks and water content.
Practical scope. These claims are formulation-level but still polymorph-defined. In litigation, the critical question is whether the accused product’s rifaximin polymorph, as manufactured and present in the dosage form, meets the XRPD peak set and any water-content limits.
How do the dependent claims shift the “fingerprint” boundary for δ and ε?
The dependent claim set for δ includes multiple “layers”:
- Minimal δ fingerprint: Claim 1 (3 peaks)
- Intermediate δ fingerprints: Claims 2-4 and others adding select peaks (example: Claims 2-4 require 11.3 or 7.1/21.5 or 6.7)
- Broad δ fingerprint: Claim 5 reciting a large peak list
- Moisture-qualified δ: Claims 6-7
- Mirrored formulation versions: Claims 24-32 and 36-44
For ε:
- Minimal ε fingerprint: Claim 8 (3 peaks)
- Intermediate/broader ε fingerprints: Claims 22-23 (and mirrored in formulation claims 34-35)
Litigation consequence: A plaintiff can plead multiple infringement theories across dependent claim variants, increasing leverage if the accused material is near the boundaries of the XRPD tolerances or if measurement interpretation differs.
What is the legal “center of gravity” of US 8,741,904: compound identity or therapeutic use?
Compound identity dominates. Every “active ingredient” claim is defined through XRPD peak sets. Method and medicinal preparation claims incorporate those same XRPD-defined polymorph requirements.
Therefore, infringement turns on analytically proving polymorph match under the patent’s defined XRPD parameters:
- Peak positions (2-θ) within the stated ±0.2°
- Presence/absence of additional peaks in dependent claims
- For δ-water claims, the measured water content falling in the specified range
This is the highest-value pathway for a defendant: challenge the ability to classify the accused rifaximin as “polymorph δ” or “ε” as claimed.
How strong is the patent estate for competitors: what are the main freedom-to-operate pressure points?
1) Polymorph switching during development and scale-up
The largest technical risk for competitors is accidental or unavoidable formation of δ (or ε) during manufacture, milling, drying, storage, or granulation. Even if development starts with a different polymorph, processing can shift solid form distributions.
2) Moisture control
For δ, claim coverage includes explicit water-content windows (2.5%–6% and 3%–4.5%). Competitors targeting an XRPD mismatch can still face claim capture if the process yields the correct δ XRPD and moisture falls within the tested range for the asserted dependent claims.
3) XRPD measurement conditions
XRPD is sensitive to:
- Instrument, wavelength, detector settings
- Sample preparation, preferred orientation, grinding
- Background subtraction and peak picking algorithms
- Relative intensity thresholds
The patent claims use peak position tolerances, which means the defendant will attack measurement methodology and peak assignments to argue the material does not satisfy the claimed fingerprint.
4) Dosage form mediation
Even if the raw material polymorph is controlled, the final drug product must maintain the claimed polymorph identity at testing time. Formulation components and storage can change solid form equilibrium.
What generic entry risks exist under US 8,741,904 (Paragraph IV and beyond)?
If US 8,741,904 is listed in FDA’s Orange Book for a rifaximin drug, generic applicants face two major risk paths:
-
Active polymorph infringement theory
The ANDA product can be tested and found to contain the claimed δ or ε polymorph per XRPD criteria. In that scenario, a Paragraph IV challenge must establish:
- non-infringement (XRPD/water mismatch), and/or
- invalidity, and/or
- unenforceability (not covered by the claim-text provided).
-
Method-of-use and formulation theory
Even if a product is approved for an existing GI indication, method claims can be pleaded for treating bacterial activity, infectious diarrhea, or anaerobic GI bacteria, provided the product contains the claimed polymorph.
Because the claims include oral and topical preparations, the entry risk depends on the competitor’s intended dosage forms and solid-state design.
What would be the primary design-around strategy versus US 8,741,904?
Based on the claim structure supplied, the design-around strategy is analytic:
-
Avoid polymorph δ and ε matching the asserted XRPD peak sets
Engineer a solid form with different peak positions outside ±0.2° tolerances and/or different additional-peak patterns.
-
For δ, control moisture to fall outside asserted water windows where targeted
If targeting dependent claims 6-7, manage water content outside the specified ranges in the final product state. (This does not eliminate risk for claim 1 if water is not a required element there.)
-
Use polymorph purging and release testing anchored to claimed fingerprint
Solid-state release criteria should directly test for peak positions and the required/forbidden peaks.
Key takeaways
- US 8,741,904 protects rifaximin polymorphs δ and ε as defined by XRPD peak position “fingerprints”; δ also includes water content windows in dependent claims.
- The claim set extends to method-of-use (GI bacterial activity) and medicinal preparations for oral and topical administration, but all hinge on the same polymorph-defined XRPD criteria.
- Competitive risk is highest if manufacturing yield or stability produces rifaximin whose XRPD peaks match the claimed δ or ε patterns and (for δ-water dependent claims) falls within the claimed moisture range.
- Freedom-to-operate defenses most often focus on polymorph classification via XRPD and water-content measurement rather than on general rifaximin pharmacology or known dosing.
FAQs
1) Does US 8,741,904 require proving water content to infringe the broadest δ claim?
No. The broadest δ compound claim provided (Claim 1) is defined by XRPD peaks only; water content appears in dependent claims (Claims 6-7 and mirrored formulation dependents).
2) Can a product be non-infringing by matching the three “core” δ peaks but missing one dependent claim peak?
If the asserted claim is a dependent one, missing required additional peaks can avoid that dependent claim. However, the plaintiff may still assert the broader independent or different dependent variants that match the accused fingerprint.
3) Are the ε claims limited to oral use?
The claim set includes oral medicinal preparation (Claims 33-35) for ε, and separate method claims (Claim 14-18) that specify oral administration as a limitation in dependent claims. The provided topical claims are for δ, not ε.
4) What measurement issues matter most for XRPD-based infringement?
Peak picking and assignment around the claimed 2-θ positions, plus sample preparation and instrument conditions, are central because the claims use tight tolerances of ±0.2°.
5) Does US 8,741,904 cover both infectious diarrhea and anaerobic bacteria?
Yes via dependent method claims for both δ (Claims 10-11) and ε (Claims 15-16), each within the GI bacterial activity framework.
References (APA)
- United States Patent. US 8,741,904. (Rifaximin polymorphic forms δ and ε; XRPD-defined peaks; GI bacterial activity methods; oral and topical preparations).
